Proton Pump Inhibitors
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Proton Pump Inhibitors (e.g., Lansoprazole, Nexium) |
| FDA Approval | Yes (for heartburn and acid-related issues) |
| Used for | Investigational use in enhancing sensitivity of cancer cells to chemotherapy |
| Clinical Trial Phase | Preclinical studies and observational studies in animals and humans |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Common PPI side effects include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness |
| OS without | Not specified |
| OS with | Studies suggest PPIs may improve progression-free survival in cancer treatment |
| PFS without | 7.5 months in metastatic breast cancer patients receiving only chemotherapy |
| PFS with | 9.5 months with 100 mg Nexium; 10.9 months with 80 mg Nexium |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: PPIs, commonly used for acid-related stomach issues, may suppress tumor growth by disrupting cancer cells' acid extrusion. Pre-treatment with PPIs has shown to sensitize cancer cells to cytotoxic drugs and improve treatment outcomes in preliminary studies. Further research is necessary to understand the optimal dosing and clinical efficacy in human cancer treatment.
From Ben Williams Book: Not specified
Loading comments...
